Chlorfenamine + Phenylpropanolamine - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Included in the formulation

АТХ:

A.01.B.A.51 Phenylpropanolamine in combination with other drugs

Pharmacodynamics:

Chlorphenamine - blocator H₁receptors. Has antihistamine, antiserotonin, anticholinergic, sedative effect. Narrows the vessels of the nasal cavity, depresses the symptoms of allergic rhinitis: rhinorrhea, sneezing, itching of the nose and eyes.

Phenylpropanolamine - α and δ-adrenomimetic, causes narrowing of the vessels of the nasal mucosa, depresses the food center of the hypothalamus, increases myocardial contractility, increases the heart rate and the minute volume of the heart.

Pharmacokinetics:

Chlorphenamine

After ingestion, up to 30% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 2.5 hours. The connection with plasma proteins is 70%. The therapeutic effect develops 1 hour after admission and lasts for 24 hours. Penetrates through the blood-brain barrier.

Metabolism in the liver.

The elimination half-life is 2 hours. Elimination by the kidneys.

Phenylpropanolamine

After oral administration, it is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 1.5-2 hours. It is subject to partial metabolism in the liver.

The half-life is 6-7 days. Elimination by the kidneys, mostly unchanged.

Indications:

It is used for the treatment of sinusitis and rhinitis, including allergic component.

ICD-10

X.J00-J06.J00 Acute nasopharyngitis (runny nose)

X.J00-J06.J01 Acute Sinusitis

X.J30-J39.J30 Vasomotor and allergic rhinitis

Contraindications:

Pheochromocytoma, arterial hypertension, heart failure, angle-closure glaucoma, bronchial asthma, children under 12 years of age, individual intolerance.

Carefully:

Hypersensitivity.

Pregnancy and lactation:

Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

Dosing and Administration:

Inside, 1 capsule 2 times a day.

Side effects:

Central and peripheral nervous system: drowsiness, headache, agitation, dizziness, tremor, convulsions, hallucinations.

Hemopoietic system: thrombocytopenia, agranulocytosis.

The cardiovascular system: tachycardia, arterial hypertension.

Digestive system: dry mouth, nausea, anorexia, gastralgia.

Musculoskeletal system: muscle tremor.

Dermatological reactions: rash, hyperhidrosis, photosensitivity.

Sense organs: mydriasis, paresis of accommodation, visual impairment.

Urinary system: retention of urine.

Reproductive system: prostate adenoma.

Allergic reactions.

Overdose:

Irritability, headache, arrhythmia, tachycardia, vomiting, hypertension, convulsions.

Treatment is symptomatic.

Interaction:

Incompatible with ethanol.

It is combined with paracetamol.

Reduces the hypotensive effect of guanethidine.

Simultaneous use with monoamine oxidase inhibitors, furazolidone increases the risk of developing hypertension.

Simultaneous use with halothane increases the risk of ventricular arrhythmia.

Enhance the sympathomimetic effect of tricyclic antidepressants.

Special instructions:

In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

Instructions

Chlorfenamine + Phenylpropanolamine (Chlorphenaminum + Phenylpropanolaminum)